Key Highlights

● Regeneron was the S&P 500's top gainer on Friday, October 30, 2026.

● Third-quarter non-GAAP Earnings of $20.07 a share beat the $16.24 consensus.

● An expanded Sanofi deal brings $1 billion upfront.

● The FDA approved a new product called Pasatru.

Regeneron Pharmaceuticals (NASDAQ:REGN) was the S&P 500's top gainer on Friday, October 30, 2026, soaring on a day when most of the market headed sharply lower. Reports differed on the size of the move, with intraday readings below the closing figure, but every account had the Tarrytown, New York-based biotech at or near the top of the leaderboard.

The rally came on several fronts at once. Third-quarter Revenue reached $5.12 billion, well ahead of the $4.54 billion analysts had expected. Non-GAAP earnings came in at $20.07 a share, against a consensus of $16.24. Market reports said that the company also raised its full-year outlook.

Sanofi money and a new approval

According to market data, Regeneron is set to receive $1 billion upfront from an expanded deal with Sanofi (NASDAQ:SNY), its longtime partner, and won Food and Drug Administration approval for a product called Pasatru. The combination gave investors a fresh cash infusion and a new commercial opportunity on top of a quarter that cleared expectations by a wide margin.

Sanofi's US-listed shares rose too. A market headline said the French drugmaker beat third-quarter expectations and raised its 2026 sales forecast.

Health care became the place to hide

Regeneron's surge fit a broader pattern. As investors fled chipmakers and megacap technology, health care hit a record high, according to market data, and was one of six S&P 500 sectors to finish in positive territory. Energy, consumer staples and utilities also advanced.

The rotation lifted a long list of drug and medical names. Gilead Sciences (NASDAQ:GILD) climbed after third-quarter non-GAAP earnings of $2.55 a share crushed estimates. AbbVie (NYSE:ABBV) hit a 52-week high after raising its full-year adjusted earnings guidance, and Eli Lilly (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also reached 52-week highs. AstraZeneca (NASDAQ:AZN) gained after a profit beat.

The backdrop elsewhere was grim. The S&P 500 fell 140.32 points to 7,580.07 and the Nasdaq Composite dropped 747.73 points to 25,437.00, its worst day since June 5. The Nasdaq-100, where Regeneron is a member, closed at 28,384.85. The Dow Jones Industrial Average lost 572.25 points to 51,770.31.

Intel (NASDAQ:INTC)'s weak guidance and cash-burn warning drove a collapse in semiconductors, while Amazon (NASDAQ:AMZN)'s negative trailing free Cash Flow and Alphabet (NASDAQ:GOOGL)'s record selloff on Thursday deepened worries about AI spending. "A lot of them kind of got ahead of themselves. It's all earnings based and right now, they're not producing," a trading specialist said.

Why the contrast mattered

Regeneron's day captured the split in the market. Investors punished companies whose spending outran their cash generation and rewarded companies that delivered profits above expectations. A quarter that beat on both revenue and earnings, backed by partner cash and a new product, was the kind of story buyers were looking for on Friday.

Interest rates remain a Factor for all stocks. The Federal Reserve held its benchmark rate range steady this week in a 10-2 vote, and markets have priced in a December hike. Chair Kevin Warsh said at his press conference: "But Inflation remains elevated."

What to watch

Investors will look for more detail on the expanded Sanofi arrangement and on the commercial rollout of Pasatru. Whether the raised full-year outlook holds up through the fourth quarter will be the next test.

For the sector, the question is whether the defensive rotation persists. Pfizer reports Tuesday, November 3, the same day as the midterm elections, and the October jobs report arrives Friday, November 6. Those events will help show whether health care can keep its Leadership while the tech trade wobbles.